US 12,220,444 B2
Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
Tracey L. McLaughlin, Stanford, CA (US); and Colleen M. Craig, Stanford, CA (US)
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Palo Alto, CA (US)
Filed by THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Filed on Feb. 22, 2023, as Appl. No. 18/172,543.
Application 18/172,543 is a continuation of application No. 17/226,161, filed on Apr. 9, 2021, granted, now 11,622,995, issued on Apr. 11, 2023.
Application 17/226,161 is a continuation of application No. 16/813,536, filed on Mar. 9, 2020, granted, now 10,993,992, issued on May 4, 2021.
Application 16/813,536 is a continuation of application No. 15/576,646, granted, now 10,660,937, issued on May 26, 2020, previously published as PCT/US2016/033836, filed on May 23, 2016.
Claims priority of provisional application 62/329,850, filed on Apr. 29, 2016.
Claims priority of provisional application 62/254,175, filed on Nov. 11, 2015.
Claims priority of provisional application 62/165,743, filed on May 22, 2015.
Prior Publication US 2023/0346890 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61K 45/06 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01)
CPC A61K 38/2278 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 38/17 (2013.01); A61K 38/22 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); A61P 3/08 (2018.01)] 19 Claims
 
1. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising subcutaneously administering to the subject in need thereof a therapeutically effective amount of exendin (9-39), wherein the therapeutically effective amount is 2-100 mg.